drug · antibody
riliprubart
Phase 3updated 3mo agoby $SNY Sanofi🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 7 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying riliprubart
- phase3Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
- phase3A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
- phase3A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
News(3)
- Sanofi stops immune drug trial in latest research setbackThe failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.biopharma_dive · 2mo ago
- STAT+: Hope for Kendall Square’s lab marketDrug pricing in Europe, AI deals for VC firms, and more biotech news from The Readoutstat · 2mo ago
- Sanofi to mull riliprubart’s future after stopping late-stage nerve disease studySanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely to show sufficient efficacy. The broader future of t…endpoints · 2mo ago
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that